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Abstract
Background: Klebsiella spp. are opportunistic pathogens which can cause severe infections, are often multi-drug
resistant and are a common cause of hospital-acquired infections. Multiple new Klebsiella species have recently
been described, yet their clinical impact and antibiotic resistance profiles are largely unknown. We aimed to explore
Klebsiella group- and species-specific clinical impact, antimicrobial resistance (AMR) and virulence.
Methods: We analysed whole-genome sequence data of a diverse selection of Klebsiella spp. isolates and identified
resistance and virulence factors. Using the genomes of 3594 Klebsiella isolates, we predicted the masses of 56
ribosomal subunit proteins and identified species-specific marker masses. We then re-analysed over 22,000 Matrix-
Assisted Laser Desorption Ionization - Time Of Flight (MALDI-TOF) mass spectra routinely acquired at eight
healthcare institutions in four countries looking for these species-specific markers. Analyses of clinical and
microbiological endpoints from a subset of 957 patients with infections from Klebsiella species were performed
using generalized linear mixed-effects models.
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Results: Our comparative genomic analysis shows group- and species-specific trends in accessory genome
composition. With the identified species-specific marker masses, eight Klebsiella species can be distinguished using
MALDI-TOF MS. We identified K. pneumoniae (71.2%; n = 12,523), K. quasipneumoniae (3.3%; n = 575), K. variicola
(9.8%; n = 1717), “K. quasivariicola” (0.3%; n = 52), K. oxytoca (8.2%; n = 1445), K. michiganensis (4.8%; n = 836), K.
grimontii (2.4%; n = 425) and K. huaxensis (0.1%; n = 12). Isolates belonging to the K. oxytoca group, which includes
the species K. oxytoca, K. michiganensis and K. grimontii, were less often resistant to 4th-generation cephalosporins
than isolates of the K. pneumoniae group, which includes the species K. pneumoniae, K. quasipneumoniae, K. variicola
and “K. quasivariicola” (odds ratio = 0.17, p < 0.001, 95% confidence interval [0.09,0.28]). Within the K. pneumoniae
group, isolates identified as K. pneumoniae were more often resistant to 4th-generation cephalosporins than K.
variicola isolates (odds ratio = 2.61, p = 0.003, 95% confidence interval [1.38,5.06]). K. oxytoca group isolates were
found to be more likely associated with invasive infection to primary sterile sites than K. pneumoniae group isolates
(odds ratio = 2.39, p = 0.0044, 95% confidence interval [1.05,5.53]).
Conclusions: Currently misdiagnosed Klebsiella spp. can be distinguished using a ribosomal marker-based approach
for MALDI-TOF MS. Klebsiella groups and species differed in AMR profiles, and in their association with invasive
infection, highlighting the importance for species identification to enable effective treatment options.
Keywords: MALDI-TOF MS, Klebsiella spp., Invasive infections, Antimicrobial resistance, Species identification
Background
Klebsiella spp. are opportunistic pathogens, resident as re-
spiratory and intestinal microbiota, and are commonly iso-
lated during severe infections such as sepsis, pneumonia
and pyelonephritis [1, 2]. Particularly hypervirulent strains
of K. pneumoniae, which have been linked to specific cap-
sular factors resulting in a muco-viscous phenotype, cause
pyogenic liver abscesses and sepsis [3, 4]. In addition, the
number of multi-drug resistant (MDR) isolates is increasing
globally, carrying plasmids encoding for extended spectrum
beta-lactamase (ESBL) or carbapenemase genes [5, 6]. K.
pneumoniae is part of the ESKAPE pathogens (Enterococcus
faecium, Staphylococcus aureus, Klebsiella pneumoniae,
Acinetobacter baumannii, Pseudomonas aeruginosa, En-
terobacter) which were classified by the WHO in 2017 as
critical priority pathogens for research and development of
new antibiotic treatment modalities [7].
The taxonomy of the genus Klebsiella has been in flux
for the past few years, divided into two main groups: the
K. pneumoniae and the K. oxytoca group. Recently, several
new species have been described within the K. pneumo-
niae group, which includes K. pneumoniae (sensu stricto),
K. quasipneumoniae [8], K. variicola [9], “K. quasivarii-
cola” [10] and K. africana [11]. The K. oxytoca group
comprises K. oxytoca (sensu stricto), K. michiganensis
[12], K. grimontii [13], K. spallanzanii and K. pasteurii
[14]. K. huaxensis [15] is more closely related to the K.
oxytoca group than to the K. pneumoniae group, but
forms a distinct clade (Fig. 1A). Most of the Klebsiella spp.
have been observed within a clinical context [10, 13–17].
The K. oxytoca group has been reported to cause
antibiotic-associated hemorrhagic colitis in neonates, and
hospital-acquired infections such as pneumonia and urin-
ary tract infections (UTI) [18, 19]. Previous studies have
analysed the population structure of a subset of Klebsiella
spp. [10, 20, 21]. The gained knowledge from these studies
could however not yet be translated to clinical routine
diagnostics, and the clinical relevance of these recently de-
scribed Klebsiella spp. is still unclear.
The newly described Klebsiella spp. are not yet identi-
fied with routine hospital-based diagnostic procedures.
Biochemical reaction profiling cannot distinguish between
all Klebsiella spp. [16, 22], neither is 16S rRNA a good se-
quencing target for species distinction within Enterobacte-
riaceae [23]. The most widely used technology for
bacterial species identification in microbiological routine
diagnostics is Matrix-Assisted Laser Desorption Ionization
- Time Of Flight Mass Spectrometry (MALDI-TOF MS)
[24]. The two commonly used commercial databases
(MALDI Biotyper (MALDI Biotyper Compass Library, Re-
vision E (Vers. 8.0, 7854 MSP, RUO) Bruker Daltonics,
Bremen, Germany) and VitekMS DB (v.3.2, bioMérieux,
Marcy-l’Étoile, France) allow spectral identification of K.
pneumoniae, K. variicola and K. oxytoca. Importantly, “K.
quasivariicola”, K. quasipneumoniae, K. africana, K.
michiganensis, K. grimontii, K. pasteurii, K. spallanzanii
and K. huaxensis are currently not included in these data-
bases, and strains of these species are wrongly identified
as either K. pneumoniae or K. oxytoca using MALDI-TOF
MS [16]. Fortunately, recent developments show that a
distinction of Klebsiella spp. is possible in routine diagnos-
tics, using Fourier-transform infrared spectrometry [25]
and MALDI-TOF MS using alternative databases [26].
Ribosomal subunit proteins are suitable as phylogen-
etic protein markers for MALDI-TOF mass spectra, as
they are highly abundant in replicating cells and of rela-
tively low molecular weight [27, 28]. Combinations of
ribosomal subunit protein-derived masses allow the
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separation of sub-lineages within Escherichia coli [29]
and Streptococcus agalactiae [30] by MALDI-TOF MS.
The aim of our study was to investigate the clinical
presentation and distribution of AMR and virulence
across the genus Klebsiella. Furthermore, using
whole-genome sequences, we aimed to develop a
ribosomal subunit-based MALDI-TOF MS scheme to
robustly distinguish between Klebsiella spp. in clinical
routine and to apply this on a large international
dataset.
Fig. 1 Genomic content of isolates across the Klebsiella genus. A Core-genome phylogeny of the genus Klebsiella including isolates from K. pneumoniae (n =
218), K. quasipneumoniae (n = 83), “K. quasivariicola” (n = 5), K. variicola (n = 109), K. oxytoca (n = 41), K. michiganensis (n = 54), K. grimontii (n = 37) and K.
huaxensis (n = 1) based on 1171 core genes. The species colour key is used throughout the figure and paper. B Pan- (upper) and core- (lower) gene
accumulative curves comparing K. pneumoniae group and K. oxytoca group. C Number of plasmid replicons identified in each isolate, per species. Boxes
indicate the IQR with the median displayed as middle lines. D Plasmid replicons identified by PlasmidFinder in all isolates (n = 548), shown per Klebsiella spp
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Methods
An outline of the study method is given in Additional
file 1: Figure S1.
Ethics
Bacterial strains have been collected in clinical routine
diagnostics. The collection of bacterial strains and their
analysis for diagnostic assay development do not fall
under the Swiss human research act, and no ethical ap-
proval nor consent to participate from patients was re-
quired. The analysis of patient demographic and clinical
outcome data was approved by the “Ethikkommission
Nordwest- und Zentralschweiz” (EKNZ) (BASEC-Nr.
2016-01899 and 2018-00225) for patients who did not
reject the hospitals general research consent. Patients
who did reject the hospital’s general consent were ex-
cluded from all analyses which include patient demo-
graphic and clinical outcome data.
Bacterial isolates and whole-genome sequencing (WGS)
In total, 261 Klebsiella spp. isolates were collected from
various tissue sources (see Additional file 2: Table S1 for
more details) at three routine diagnostic laboratories in
Switzerland including the University Hospital of Basel
(USB; Basel, Switzerland), Mabritec AG (Riehen,
Switzerland) and Labor Team W AG (LTW; Goldach,
Switzerland)). Isolates were grown on Columbia 5%
Sheep Blood Agar (bioMérieux, Marcy-l’Étoile, France),
and DNA was extracted using the QIACube with the
QIAamp DNA Mini Kit (QIAGEN, Hilden, Germany).
After quality control of the DNA by Tapestation (Agi-
lent, Santa Clara, USA), tagmentation libraries were gen-
erated as described by the manufacturer (Nextera XT
kit, Illumina, San Diego, USA). The genomes were se-
quenced under 24× multiplexing using a 2 × 300 base
pairs V3 reaction kit on an Illumina MiSeq instrument
reaching an average coverage of approximately 60-fold
for all isolates. Eleven isolates, covering reference and
clinical isolates of 6 species were additionally sequenced
on a PacBio Sequel at the Functional Genomics Center
Zurich (FGCZ, ETH Zurich, Switzerland).
All available whole-genome assemblies designated as
Klebsiella spp. were downloaded from NCBI in Decem-
ber 2017 (n = 3047), representing members of the spe-
cies K. pneumoniae, K. quasipneumoniae, K. variicola,
“K. quasivariicola”, K. oxytoca, K. michiganensis, K. gri-
montii, K. huaxensis, K. aerogenes and three species of
the genus Raoultella (R. ornithinolytica, R. planticola
and R. terrigena). An additional selection of publicly
available K. pneumoniae whole-genome sequences were
included from NCBI SRA, which was sampled to
maximize diversity (n = 286) [20]. Two sets of Klebsiella
spp. genomes were used for this study: first, a total of n
= 3594 publicly available genome sequences including
the 3333 described above, and the 261 sequenced at the
USB, were used to in silico predict ribosomal protein
masses. The species identity of these genome sequences
were determined by comparison to the typestrains of K.
pneumoniae, K. quasipneumoniae, K. variicola, “K. qua-
sivariicola”, K. oxytoca, K. michiganensis, K. grimontii, K.
huaxensis R. ornithinolytica, R. planticola and R. terri-
gena using Average Nucleotide Identity (ANIm) [31] and
a threshold of 96%. Second, a computationally more
manageable subset of these genomes (n = 999) was used
for comparative genomic analyses, selected to represent
the largest genomic diversity between and within species,
and geographically. This subset included all assemblies
of K. quasipneumoniae, K. variicola, “K. quasivariicola”,
K. oxytoca, K. michiganensis, K. grimontii and K. huax-
ensis. For K. pneumoniae, only strains sequenced at USB
and the previously published, diverse set of sequences
[20] were included. To avoid bias introduced by out-
break strains, we excluded genomes which shared
ANIm values > 99.9% with another genome in the col-
lection, resulting in a final dataset of n = 548 genomes.
Both datasets, including accession numbers and those of
the short and long reads sequenced for this study, can
be found in Additional file 2: Table S1. K. africana, K.
pasteurii and K. spallanzanii were not included in this
analysis as the species were not published at the time of
the analysis and are extremely rare in clinics.
Comparative genomic analysis
WGS data was quality controlled using FastQC [32] and
MetaPhlAn (v2.0) [33] and adaptors were trimmed using
Trimmomatic [34]. Genome assemblies were created
using Unicycler (v0.4.4) [35]. Prokka (1.12) [36] was used
for annotation. Orthologous groups were built using
Roary (v3.10.2, option: -i 90) [37]. The resulting core-
genome alignment was used for the construction of a
phylogenetic tree using FastTree (v2.1) [38, 39]. The
sizes of the core- and pan-genomes were calculated
u s i n g a p y t h on s c r i p t ( h t t p s : / / g i t h u b . c om /
appliedmicrobiologyresearch/Klebsiella-spp) [40].
The O-loci and K-loci were determined using KLEBO-
RATE (v0.3.0) [41–43]. The genomes were investigated
for the presence of known virulence loci (those included
in KLEBORATE and the cytotoxin tilivalline [44]) and
AMR determinants (via KLEBORATE). Potential plas-
mids were detected by comparing the genomes to the
PlasmidFinder database [45] using abricate [46]. Gen-
omic analyses were performed at sciCORE (http://
scicore.unibas.ch/) scientific computing centre at Uni-
versity of Basel.
Scripts generating figures from the output of these
tools were deposited on Github (https://github.com/
appliedmicrobiologyresearch/Klebsiella-spp) [40].
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In silico prediction of ribosomal subunit protein masses
from WGS data
The molecular weight of 56 ribosomal subunits was pre-
dicted in silico as described [26]: Tblastn (v 2.2.31+) was
used to extract the amino acid sequences of 56 riboso-
mal subunits from 3594 Klebsiella spp. assemblies. Full
ribosomal subunit sequences were retained when start
and stop codons were identified and the length was
within the median ± 3 codons. The subunits L1, L2 and
S12 were not found in over 90% of the genomes and
were therefore excluded from further analysis. The ribo-
somal subunit protein S1 was also excluded because S1-
like domains are found in proteins unrelated to the ribo-
some [41]. The masses of the ribosomal subunit protein
alleles were predicted including the N-end rule to ac-
count for possible methionine loss at the N-terminus
[47]. The mass of subunit L33 was corrected by 15 Da to
account for post translational methylation [48].
Definition of species-specific MALDI-TOF MS marker
masses
A diverse selection of bacterial isolates (n = 50) repre-
senting at least eight isolates of K. pneumoniae, K. varii-
cola, K. oxytoca, K. michiganensis and K. grimontii,
whole-genome sequenced for this study, were used to
validate the detection of the predicted marker masses in
MALDI-TOF mass spectra. These represent the most
common species within the K. pneumoniae and the K.
oxytoca group [5, 20, 21]. MALDI-TOF mass spectra of
these 50 Klebsiella isolates were acquired on four
MALDI-TOF MS systems in different laboratories, in-
cluding one microflex Biotyper (Bruker Daltonics, Bre-
men, Germany) at the USB (Basel, Switzerland), one
Axima Confidence (Shimadzu, Ngoyo, Japan) at Mabri-
tec AG (Riehen, Switzerland) and two VitekMS devices
(bioMérieux, Marcy-l’Étoile, France) at the Laborge-
meinschaft 1 (LG1) (Zürich, Switzerland) and the Ente
Ospedaliero Cantonale (Bellinzona, Switzerland). The
Klebsiella isolates were measured on each system in
quadruplicate using direct smear method and overlaid
with formic acid (70% for the spectra acquired on the
Microflex Biotyper and 25% for all other machines) and
cyano-4-hydroxycinnamic acid (CHCA) matrix solution.
MALDI-TOF mass spectra acquired on the VitekMS
(bioMérieux, Marcy-l’Étoile, France) (n = 400 spectra)
were output as .mzml files containing a list of peaks per
spectrum. For MALDI-TOF mass spectra acquired on
the Axima Confidence (n = 200 spectra) peak picking
was performed using the Launchpad Software (v2.8, Shi-
madzu, Ngoyo, Japan) (parameters: scenario: “Ad-
vanced”; peak width: 80 chans; smoothing method:
“Average”; smoothing filter width: 500 chans; peak de-
tection method: “Threshold-Apex”; threshold type: “dy-
namic”; threshold offset: 0.025 mV; threshold response
1.25×). MALDI-TOF mass spectra acquired on a micro-
flex Biotyper (n = 200 spectra) were output as fid-files
and peak picking was performed in the flexAnalyses
software (v3.4) (parameters: peak detection: “Centroid”;
signal to noise threshold: 2; relative intensity threshold:
0%; minimal intensity threshold: 600; maximal number
of peaks: 300; peak width: 4 m/z; peak height: 90%; base-
line subtraction: “TopHat”; smoothing algorithm:
“Savitzky Golay”; smoothing width: 2 m/z; smoothing cy-
cles: 10). All MALDI-TOF mass spectra were internally
calibrated with the conserved masses 4365.3 m/z, 6383.5
m/z, 7158.7 m/z, 7244.5 m/z, 10,286.1 m/z and a toler-
ance range of 1000 ppm, using the R-packages MALDI-
Quant and MALDIQuantForeign [49]. All spectra were
exported in ASCII format and interrogated for the ribo-
somal subunit protein allele masses predicted from the
respective WGS data. We used the following criteria to
select the ribosomal target proteins for subsequent spe-
cies identification, in order to maximize discriminatory
power and reproducibility: ribosomal subunit protein
masses in the mass range from 3000–13,000 Da (L36,
S22, L34, L30, L32, L33, L35, L29, L31, S21, L27, S20,
S15, S19, L25, S14, L21, L18) were selected if they were
detected with a reproducibility > 80% in a least one
centre, with the exception of ribosomal subunit L28,
which had a maximal reproducibility of 57%. Addition-
ally, ribosomal subunit protein masses in the higher
mass range from 13,000 to 15,000 Da (L19, S13, L20, S8,
L17, S9) were included, as they were detected with a re-
producibility of at least 35% in at least one centre. Ribo-
somal subunits with a predicted molecular weight >
15,000 Da were not included for further analysis.
The bacterial species was assigned for which most
marker masses could be detected in the acquired mass
spectrum. If in a spectrum an equal number of marker
masses from different Klebsiella species were found, the
spectrum was assigned a multi-species ID (e.g. K. michi-
ganensis / K. oxytoca) and labelled as “Multispecies ID
only”.
Classification of MALDI-TOF mass spectra acquired in
routine microbiology diagnostics
Routinely acquired MALDI-TOF mass spectra (n =
33,160) from eight international healthcare institutions
from four countries were analysed: the Soroka Medical
Centre (SMC; Beer Sheva, Israel); the Hospital General
Universitario Gregorio Marañón (HGUM; Madrid,
Spain); the Servizio di microbiologia EOLAB, Ente Ospe-
daliero Cantonale (Bellinzona, Switzerland); the LG1,
(Zurich, Switzerland); the LTW (Goldach, Switzerland);
the USB (Basel, Switzerland); the Maastricht University
Medical Center (MUM; Maastricht, the Netherlands)
and the University Medical Center Groningen (UMCG;
Groningen, the Netherlands). The MALDI-TOF mass
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spectra were processed as described above. Each rou-
tinely acquired spectrum was interrogated for the pres-
ence of the reproducibly detected ribosomal protein
subunit derived mass combinations, with an accepted
error range of 300 ppm. In total, 10,814 MALDI-TOF
mass spectra were from duplicated bacterial isolates and
excluded from further analysis, leading to a final number
of 22,346 MALDI-TOF mass spectra representing
unique bacterial isolates.
Phenotypic profiling
The same collection of Klebsiella spp. strains (n = 50),
which were used to define species-specific marker
masses, were subjected to biochemical profiling on a
Vitek2 (bioMérieux, Marcy-l’Étoile, France) using the
GN ID card and the API50ch panel (bioMérieux, Marcy-
l’Étoile, France). Primary metabolites of the same strains
were measured and analysed as described in Additional
file 3: Supplementary Methods. Additionally, 11 strains
were subject to fatty acid profiling as described in Add-
itional file 3: Supplementary Methods. These 11 strains
included reference strains of the species K. pneumoniae,
K. quasipneumoniae, K. variicola, K. oxytoca and K.
michiganensis, one clinical isolate for each of the species
K. pneumoniae, K. variicola, K. oxytoca and K. michiga-
nensis and two clinical isolates of the species K.
grimontii.
Antimicrobial resistance determination
AMR profiles of isolates associated with the retrospect-
ively analysed spectra were accessed through the labora-
tory information systems of the USB and the LTW (n =
7876). The accessed AMR profiles were measured in
clinical routine diagnostics from January 2015 to June
2018 using either microdilution methods (Vitek2, AST-
N242 GN Cards, bioMérieux), MIC strip tests (Liofil-
chem, Roseto degli Abruzzi, Italy) or disc diffusion tests
(ThermoFisher Scientific, Waltham, USA). Breakpoints
were interpreted as susceptible or resistant according to
the current EUCAST Breakpoint table (v6.0 – 8.1) [50].
Retrospective assessment and statistical analysis of
clinical data
We assessed the relative distribution of Klebsiella spp.
with regard to laboratory and country of isolation (n =
22,346, including spectra from eight laboratories). We
examined the association of Klebsiella groups and spe-
cies with resistance to antibiotic classes using logistic re-
gression (post hoc analyses; n = 7876, including spectra
from two laboratories).
Patient demographic and clinical data from patients
with Klebsiella spp. infections were retrospectively
accessed via the USB clinical information system in a
case report form for a subset of clinical cases (n = 957).
Inclusion criteria were as follows: patients for which at
least one isolated bacterial colony was identified as Kleb-
siella spp. by MALDI-TOF MS collected between Janu-
ary 2015 and June 2018 at the USB and who did not
reject the hospital’s general research consent form, as
approved by the ethical committee. The USB is a tertiary
healthcare centre with more than 750 beds in a low en-
demic region for ESBL-producing bacteria [51].
The clinical outcomes of 957 patients with Klebsiella
infections were analysed and included all-cause mortality
within 30 days from Klebsiella spp. diagnosis as primary
endpoint and secondary endpoints: (i) time to death
after Klebsiella spp. diagnosis in days, (ii) admission to
an intensive care unit (ICU), (iii) invasive infection to
sterile sites (including the bloodstream, deep tissues and
cerebrospinal fluids), (iv) length of hospital stay in days,
(v) the number of medical disciplines involved to man-
age the specific case (as a surrogate marker for case
complexity) and (vi) whether the infection was men-
tioned in the patient letters. Clinical outcomes were ex-
amined for an association with distinct Klebsiella spp.,
age, sex, immunosuppression (defined as a dose equiva-
lent of 20 mg prednisone / day or mentioning of im-
munosuppression in the patient notes), Charlson
Comorbidity Index (CCI) [52], resistance to 3rd-
generation cephalosporins and antibiotic treatment (de-
fined as at least one dose of antimicrobial agent at hos-
pital entry or during the hospital stay). Binary outcomes
were analysed using generalized linear mixed models
(GLMM) with binomial error distribution. Count out-
comes (number of medical disciplines involved) were
analysed using GLMM with Poisson error distribution.
Time to death within hospital and length of hospital stay
(time to discharge) were considered competing risks and
jointly analysed by a competing risks model. For further
detail, see Additional file 3: Supplementary Methods.
Results
Comparative genomic analyses of Klebsiella spp.
To determine the core-genome of the genus Klebsiella,
from the 3594 Klebsiella spp. isolates with available
WGS, a selection of 548 isolates was made, reflecting be-
tween- and within-species diversity. The genus core-
genome comprises n = 1171 genes, which are genes
shared between 99% of these 548 isolates. The core-
genome-based phylogeny (Fig. 1A) clearly shows the
Klebsiella phylogeny as previously described [5, 20, 21],
with subspecies within K. quasipneumoniae (K. quasip-
neumoniae subsp. quasipneumoniae and K. quasipneu-
moniae subsp. similipneumoniae) as well as within K.
variicola (K. variicola subsp. variicola and K. variicola
subsp. tropica) which can be distinguished. These spe-
cies also contain a diverse array of strains, in contrast to
K. pneumoniae, which is more homogeneous when
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comparing these 1171 core genes. Interestingly, K. gri-
montii includes two deeply branching sub clades, which
have not yet been described as subspecies (Fig. 1A).
The pan-genomes of the K. pneumoniae group and the
K. oxytoca group were determined by investigating the
number of unique orthologous clusters within our gen-
ome data set (Fig. 1B). A larger pan- to core-genome ra-
tio could suggest adaptation to diverse environments,
whereas a smaller pan- to core-genome ratio could, in a
clinical context, reflect adaptation to the human host or
even site-specific infections. Both groups show an open
pan-genome, with the number of unique orthologous
clusters increasing as more genomes are added to the
analysis. There seems to be a larger increase in the pan-
genome of the K. oxytoca group with strains added, al-
though fewer genomes have been sampled to date. At a
species level, pan-genome sizes of those within the K.
pneumoniae group are relatively similar, whereas K.
michiganensis within the K. oxytoca group shows a larger
pan-genome, although this may reflect sampling bias
(Additional file 1: Figure S2).
Plasmid complements are known to vary widely be-
tween Klebsiella isolates and can carry accessory genes
involved in AMR and pathogenicity [53–55]. We de-
tected a lower median number of plasmid replicons per
isolate within the K. oxytoca group (median = 2, inter-
quartile range (IQR) = 0–4) compared to isolates of the
K. pneumoniae group (median = 4, IQR = 2-4) (Fig. 1C).
The lowest median number of plasmids was detected for
K. grimontii isolates (median = 1, IQR = 0–5), and the
highest median number of plasmids detected in “K. qua-
sivariicola” (median = 7, IQR = 5–10) isolates. We also
observed that within the K. pneumoniae group, the me-
dian count of plasmids detected was lower in K. varii-
cola isolates (median = 3, IQR = 0–5) than in isolates of
the other species of the K. pneumoniae group (median =
4, IQR = 3–6 for K. pneumoniae; median = 5, IQR = 2–
7 for K. quasipneumoniae and median = 7, IQR = 5–10
for “K. quasivariicola”) (Fig. 1C). No group specificity
could be detected in plasmid replicon profiles (Fig. 1D).
The two replicons known to be particularly related to
virulence, plasmids KpVP-1 and KpVP-2, (IncHI1B_
pNDM-MAR and IncFIB(K)_Kpn3 respectively), were
detected in isolates from all Klebsiella spp. (K. pneumo-
niae n = 162/218, 73.3%; K. quasipneumoniae n = 61/83,
73.5%; K. variicola n = 56/109, 51.4%; “K. quasivariicola”
n = 4/5, 80.0%; K. oxytoca n = 18/41, 43.9%; K. michiga-
nensis n = 23/54, 42.6%; K. grimontii n = 16/37, 43.2%)
with the exception of K. huaxensis, for which only a sin-
gle genome was available for this study.
From long read genome assemblies for a subset of 11
isolates sequenced as part of this study, the plasmids as-
sembled for nine isolates agreed with the replicon find-
ings. In K. quasipneumoniae DSM-2811T, we detected a
plasmid of 4267 bp with 99.1% identity and 71% cover-
age to the K. pneumoniae plasmid pB1019, which was
not identified by PlasmidFinder. A previously unde-
scribed plasmid of 3596 base pairs was identified within
K. grimontii 606641-17, which does not carry any known
virulence or resistance factors, showing that there is fur-
ther diversity of Klebsiella spp. plasmids to discover.
Virulence factors of Klebsiella spp.
Virulence factors were investigated by comparing 548
Klebsiella spp. genomes against known databases and
virulence factors. Genes encoding the iron-chelating
siderophores aerobactin and salmochelin were detected
in a minority of isolates (n = 18/548, 3.3% and n = 21/
548, 3.8% of isolates, respectively), only within K. pneu-
moniae and K. quasipneumoniae, often co-occurring
within isolates. The siderophore yersiniabactin is more
prevalent in isolates of the K. oxytoca group (n = 111/
132, 84.1%) than in the K. pneumoniae group (n = 52/
415, 12.5%). The kfu operon, encoding an iron transport
system, was detected in isolates of all species except K.
oxytoca (n = 333/548; 60.8% of all isolates and n = 0/41;
0% within the species K. oxytoca).
The genes involved in allantoin metabolism, which en-
able Klebsiella spp. to assimilate nitrogen from this
metabolic intermediate and increase its virulence in cer-
tain infection sites, were detected in isolates of all spe-
cies (n = 132/548; 24.1%), notably in all K. oxytoca (n =
41/41; 100%) and K. grimontii (n = 37/37; 100%) isolates.
The distribution of bacterial toxin operons encoding
microcin, colibactin and tilivalline was also examined.
The complete microcin operon was detected in a few K.
pneumoniae genomes (n = 8/218; 3.7%) and in one K.
michiganensis genome (n = 1/54; 1.9%), whereas colibac-
tin was detected solely in K. pneumoniae (n = 11/218;
5.0%). In contrast, the complete tilivalline operon was
exclusively identified in isolates within the K. oxytoca
group (n = 64/132; 48.5%) particularly in isolates of K.
oxytoca (n = 29/41; 59.2%) and K. grimontii (n = 30/37;
81.1%) (Fig. 2A).
The regulator of the mucoid phenotype rmp genes
were detected in K. pneumoniae (n = 14/218; 6.4%) and
K. quasipneumoniae (n = 1/83; 1.2%). Ecotin has been
described as being able to modulate the host immune re-
sponse [56] and was detected in isolates belonging to all
species (n = 445/548; 81.2%).
We found a high diversity of K-loci in our dataset,
with 114 capsule types. KL107 was found to be the most
prevalent K-locus type across all Klebsiella spp. (107/
548; 19.5%), with the exception of K. huaxensis where
only one genome was included (KL46; Fig. 2B). KL1 and
KL2, which are associated with a muco-viscous pheno-
type and frequently detected in hypervirulent strains,
were exclusively detected in isolates of species within
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the K. pneumoniae group; KL1 was detected in isolates
of K. pneumoniae (n = 4/218; 1.8%) and K. quasipneu-
moniae (n = 4/83; 4.8%), whereas KL2 was detected in
isolates of K. pneumoniae (n = 10/218; 4.6%) and K. var-
iicola (n = 1/109; 0.9%). Within the O-loci, we found
less diversity, with 17 types. Type O1v1 is the most com-
mon in isolates of K. pneumoniae (n = 53/218, 24.3%),
K. michiganensis (n = 41/54; 75.9%) and K. grimontii (n
= 36/37; 97.2%), whereas most isolates of K. oxytoca (n
= 22/41; 53.7%) carry the O-locus OL104. The most
common combination of K- and O-loci per species were
as follows: KL107-O2v1, KL107-OL101 and KL64-O1v1
in K. pneumoniae (each 7/218; 3.2%), KL48-O5 in K.
quasipneumoniae (n = 4/83; 4.8%) and KL107-O5 in K.
variicola (n = 6/109; 5.5%). All five “K. quasivariicola”
genomes studied carry unique combinations of K- and
O-loci. Within the K. oxytoca group, the most common
combination of K- and O-loci is carried by a bigger pro-
portion of the isolates compared to the K. pneumoniae
group species: KL68-O5 in K. oxytoca (n = 7/41; 17.1%),
KL107-O1v1 in K. michiganensis (n = 11/54; 20.4%) and
K. grimontii (n = 14/37; 41.2%) were the most frequently
detected combinations.
Antimicrobial resistance genes in Klebsiella spp.
We examined the occurrence of AMR genes in Klebsi-
ella spp. (n = 548) (Additional file 1: Figure S3). We de-
tected the chromosomally encoded AmpH for strains of
the K. pneumoniae group and a beta-lactamase of the
LEN family in K. variicola isolates, which both confer
low-level resistance to beta-lactam antibiotics [57]. Fur-
ther, we detected the chromosomally encoded beta-
lactamase genes blaOXY1-blaOXY8 in genomes within the
K. oxytoca group, for which each species carries distinct
variants, as described [58].
Fewer isolates of the K. oxytoca group were found to
carry ESBL genes (8/132; 6.1%) than isolates of the K.
pneumoniae group (125/415; 30.1%). Within the K.
pneumoniae group, fewer isolates of the species K. varii-
cola were found to carry ESBL genes (14/109; 12.8%),
Fig. 2 Virulence factors across the genus Klebsiella. A Core-genome phylogeny of 548 Klebsiella spp. genomes (left, in line with Fig. 1A) with
identified virulence-related genes shown per isolate (right), coloured by species. B Polysaccharide (K-locus, left) and lipopolysaccharide (O-locus,
right) predicted serotypes of isolates grouped by species
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compared to isolates within K. pneumoniae (78/218;
35.8%), K. quasipneumoniae (32/83; 38.6%) and “K. qua-
sivariicola” (1/5; 20.0%). We observed a higher number
of K. quasipneumoniae isolates encoding carbapene-
mases (12/83; 14.4%) compared to K. pneumoniae (15/
218; 6.9%), K. variicola (9/109; 8.6%) and “K. quasivarii-
cola” (0/5; 0%). Within the K. oxytoca group, we de-
tected the highest frequency of ESBL and
carbapenemases in K. michiganensis (6/54; 11.1% and 5/
54; 9.3%, respectively) compared to K. oxytoca (both in
1/41; 2.4%) and K. grimontii (both in 2/37; 5.4%).
Klebsiella spp. identification in routine diagnostics
Given the group- and species-specific trends in accessory
genome composition and content, an accurate species
identification may have an important clinical impact. For
the strains included in this study, fatty acid analysis, GC-
MS and a panel of biochemical reactions were unable to
identify a characteristic feature that could be used to dis-
tinguish unambiguously between the included Klebsiella
spp. (Additional file 4: Table S2, Additional file 1: Figure
S4, Additional file 5: Table S3). As such, in order to find
a robust and accurate way to distinguish Klebsiella spp.
based on MALDI-TOF mass spectra, we used ribosomal
subunit proteins as species-specific MALDI-TOF MS
markers. To do this, we first in silico-predicted protein
masses of the 56 ribosomal subunit proteins from 3594
genome drafts.
Only proteins with a mass between 2000 and 20,000
Da can be detected in MALDI-TOF mass spectra, and
due to the intrinsic measurement error of MALDI-TOF
MS, not all predicted masses can be distinguished. Add-
itionally, not all ribosomal subunit proteins can be
equally ionized, and therefore detected, in similar pro-
portions. Therefore, to determine the practical value of
our approach, we examined which of these potential
marker masses can reproducibly be detected in MALDI-
TOF mass spectra of routine quality. Fifty isolates, repre-
senting the species K. pneumoniae (n = 10), K. variicola
(n = 10), K. oxytoca (n = 8), K. michiganensis (n = 12)
and K. grimontii (n = 10), all with species identification
confirmed by WGS, were analysed in quadruplicate on
four different MALDI-TOF MS systems in different la-
boratories, resulting in the generation of 800 spectra.
The 25 ribosomal subunits L17, L18, L19, L20, L21, L25,
L27, L28, L29, L30, L31, L32, L33 (methylated), L34,
L35, L36, S8, S9, S14, S13, S15, S19, S20, S21 and S22
were subsequently included as valid target proteins for
identification of Klebsiella spp. The reproducibility of
these marker masses varied between the different labora-
tories (Additional file 6: Table S4). We found a complete
set of these 25 target proteins in 3360 assemblies and
therefore based our further analyses on these predicted
mass profiles (Additional file 7: Table S5).
We assessed the distribution of the in silico-predicted
masses of these target proteins in a representative data-
set of 464 genomes, comprising those which were in-
cluded in the comparative genomic analysis and were
complete for these 25 target proteins. We identified
multiple group- and species-specific alleles for K. pneu-
moniae, K. variicola, “K. quasivariicola”, K. oxytoca and
K. grimontii (Fig. 3). No marker mass uniquely identify-
ing K. michiganensis and K. quasipneumoniae was de-
tected. In order to unambiguously separate K.
michiganensis and K. quasipneumoniae from closely re-
lated species, a combination of marker masses needs to
be detected (e.g. S15 at 10,078 Da and L25 at 10,636 Da
for K. michiganensis, Fig. 3).
Based on the differential masses of the 25 target pro-
teins, we can distinguish 110 distinct Klebsiella spp.
ribosomal mass profiles (Additional file 8: Table S6) that
allow us to distinguish K. pneumoniae, K. quasipneumo-
niae, K. variicola, "K. quasivariicola", K. oxytoca, K.
michiganensis, K. grimontii and K. huaxensis. These 110
distinct ribosomal mass profiles were subsequently in-
cluded in an in house developed reference database for
species identification. We assessed the specificity and
sensitivity of this approach, using the spectra (n = 800)
of the same diverse Klebsiella spp. isolates (n = 50). The
species identification by MALDI-TOF MS was compared
to the species identity as assigned by WGS of the identi-
cal isolate. If essential target proteins could not be de-
tected in a MALDI-TOF mass spectrum and the
acquired mass profile did not allow unique species iden-
tification, this spectrum was labelled as “Multispecies ID
only”. Table 1 shows the evaluation of the species identifi-
cation of these spectra, resulting from comparison of the
acquired MALDI-TOF mass spectra with the 110 riboso-
mal marker mass profiles. The identification was evaluated
on two levels: (i) whether the assignment to K. pneumo-
niae or K. oxytoca group was correct and (ii) whether the
correct species within each group could be assigned. Spe-
cies identification using these marker mass profiles re-
sulted generally in accurate identification and provided
better species identification within the K. oxytoca group
than the currently used commercially available databases
Microflex Biotyper Database (MALDI Biotyper Compass
Library,Revision E (Vers. 8.0, 7854 MSP, RUO) ) and the
VitekMS Database (v.3), as these databases do not include
K. grimontii and K. michiganensis.
The sensitivity and specificity of the approach (Table
1) were computed based on the identification of
MALDI-TOF mass spectra acquired on all four MALDI-
TOF MS systems. Specificity and sensitivity on group
level were > 98% using marker mass profiles, for all
tested species on all four MALDI-TOF MS systems,
reflecting a low probability of false positive results using
this approach.
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Sensitivity on the species level varied between the
MALDI-TOF MS systems, especially within the K. oxy-
toca group. For the species K. oxytoca, sensitivity at the
species level ranged from 37.5 to 100% between the four
MALDI-TOF MS systems, for K. michiganensis from 8.3
to 70.8% and for K. grimontii from 12.5 to 95.0%. Species
identification within the K. oxytoca group requires the
detection of marker masses in a high mass range and
variations in sensitivity between the MALDI-TOF MS
systems could potentially be linked to MALDI-TOF
mass spectral quality [59].
Classification of international routinely acquired MALDI-
TOF mass spectra
Using the 110 species-specific marker mass profiles, we
retrospectively analysed 22,346 spectra derived from
bacterial isolates from eight healthcare centres in four
countries (dataset (a), Additional file 1: Figures S1 and
S5). All spectra had previously been used to diagnose
isolates as Klebsiella spp. in routine diagnostic laborator-
ies. Re-analysing the spectra using the newly compiled
mass profile database, we attempted to categorize all
spectra first into the two groups and then to one of the
eight species in the database (Fig. 4A, B).
A subset of the samples (n = 427; 1.9%) were identified
as Raoultella spp. or K. aerogenes and excluded from
further analysis. In total, 85 samples (0.3%) could only
be identified to the genus level. The remaining 21,834
samples (97.7%) were categorized as K. pneumoniae
group or K. oxytoca group. Of these, a higher proportion
of samples could be categorized to the species level
within the K. pneumoniae group (n = 14,867/17,555;
84.7%), than within the K. oxytoca group (n = 2718/
4249; 64.0%), which reflects the difficulty to reproducibly
detect all required species-specific marker masses in the
K. oxytoca group. The proportion of samples which
could not be categorized to the species level varied by
healthcare centre and MALDI-TOF MS system and
ranged from 9.8% (n = 40/407 samples) to 30.5% (n =
439/1440 samples) within the K. pneumoniae group and
from 22.8% (n = 349/2560 samples) to 84.8% (n = 217/
256 samples) within the K. oxytoca group. The
remaining 17,585 samples (78.69%) could unambigu-
ously be identified to the species level. Of these, across
all centres, we identified: K. pneumoniae (n = 12,523;
71.2%), K. quasipneumoniae (n = 575; 3.3%) K. variicola
(n = 1717; 9.8%), “K. quasivariicola” (n = 52; 0.3%), K.
oxytoca (n = 1445; 8.2%), K. michiganensis (n = 836;
Fig. 3 Distribution of the in silico-predicted masses of 25 target proteins encoded by the species K. pneumoniae (n = 208), K. quasipneumoniae (n
= 60), K. variicola (n = 68), “K. quasivariicola” (n = 3), K. oxytoca (n = 37), K. michiganensis (n = 51), K. grimontii (n = 36) and K. huaxensis (n = 1)
Table 1 Evaluation of the species identification of 50 Klebsiella spp. isolates by MALDI-TOF mass spectra using ribosomal marker
mass profiles. Species identification of 800 MALDI-TOF mass spectra using 110 marker mass profiles was compared to the species
identification assigned using WGS data. Specificity and sensitivity were computed on two levels: (i) whether the assignment to K.
pneumoniae group or K. oxytoca group was correct (= “Group level”) and (ii) whether the correct species within each group could
be assigned (= “Species level”)
Species identification by WGS Identification of MALDI-TOF mass spectra using Marker Mass profiles based on 25 pre-defined ribosomal
subunit proteins
Group level Species level
Sensitivity [%] Specificity [%] Sensitivity [%] Specificity [%]
K. pneumoniae 98.8 100 70.0 100
K. variicola 98.1 100 93.1 100
K. oxytoca 99.2 100 80.5 99.4
K. michiganensis 100 100 44.3 100
K. grimontii 99.4 100 70.6 100
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4.8%), K. grimontii (n = 425; 2.4%) and K. huaxensis (n =
12; 0.1%).
Interestingly, we observed different frequencies of the
two Klebsiella groups and species depending on the ori-
ginating healthcare centre, possibly reflecting a geograph-
ical trend of pathogenic Klebsiella spp. distribution (Fig.
4A): The proportion of isolates belonging to the K.
oxytoca group was higher in more northern regions, a
finding which requires further investigation. The propor-
tion of Klebsiella groups and species was also found to
vary depending on the patient material from which it was
isolated (Fig. 4B). Isolates of the K. oxytoca group were
least abundant in urinary tract samples and most abun-
dant in samples of the gastro-intestinal tract samples.
Fig. 4 Occurrence of Klebsiella spp. in clinical settings, as determined by ribosomal marker MALDI-TOF MS method. A Occurrence of Klebsiella
groups and species in eight healthcare centres from Israel (n = 1), Spain (n = 1), Switzerland (n = 4) and the Netherlands (n = 2), sorted by
increasing occurrence of the K. oxytoca group. B Occurrence of Klebsiella groups and species in patient samples from various isolation sites.
“Primary sterile sites” includes deep wounds, aspirates and deep tissues; “Respiratory tract” includes sputum, bronchoalveolar lavage and tracheal
secretion; “Superficial swabs” includes swabs from superficial wounds and skin infections. C Antibiotic resistance of Klebsiella spp. (BENI = beta
lactams with beta-lactamase inhibitors, CEF3 = 3rd-generation cephalosporins, CEF4 = 4th-generation cephalosporins, AGLY = aminoglycosides,
CARBA = carbapenems, CHIN = quinolones, PMX = polymyxins). Please note that the colour grading is on log-scale
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AMR profiles
Information on phenotypic AMR and isolation source
was available for 7876 samples from two healthcare cen-
tres in Switzerland (USB and LTW), (dataset (b), Fig.
4C, Additional file 1: Figures S1 and S5) for which spec-
tra had been analysed. Isolates of the K. oxytoca group
were more likely to be resistant against penicillins in-
cluding beta-lactamase inhibitors and 3rd-generation
cephalosporins (OR 2.79, p < 0.001, 95% CI [1.70, 4.63];
OR 2.45, p = 0.005, 95% CI [1.31, 4.58], respectively) but
less often resistant to 4th-generation cephalosporins and
aminoglycosides (OR 0.17, p < 0.001, 95% CI [0.09,
0.28]; OR 0.22, p < 0.001, 95% CI [0.12, 0.35]) than iso-
lates of the K. pneumoniae group (Additional file 9: Ta-
bles S7 - S9). Within the K. oxytoca group we found K.
oxytoca to be less resistant to penicillins including beta-
lactamase inhibitors, than K. michiganensis (OR 0.57, p
< 0.001, 95% CI [0.42, 0.75]) (Additional file 9: Table S7).
Within the K. pneumoniae group, isolates identified as
K. pneumoniae were more resistant to penicillins includ-
ing beta-lactamase inhibitors, 3rd- and 4th-generation
cephalosporins as well as to aminoglycosides than K.
variicola (OR 2.11, p < 0.001, 95% CI [1.42, 3.18]; OR
2.61, p < 0.003, 95% CI [1.38,5.06] and OR 5.80, p <
0.001, 95% CI [2.40,20.04], respectively) (Additional file
9: Tables S8-S10).
Clinical endpoints
Data from patient charts of 957 clinical cases at the USB
were reviewed and analysed on multiple clinical end-
points (dataset (c), Additional file 1: Figures S1 and S5).
In order to examine the clinical phenotype of the Klebsi-
ella groups and species, independent of their AMR bur-
den, we corrected our model for resistance against 3rd-
generation cephalosporins, which is associated with pro-
duction of ESBL. Clinical outcomes and explanatory
variables are summarized in Additional file 10: Tables
S11-S12.
We found no evidence for Klebsiella group- or
species-specific association with our primary 30-day
mortality endpoint (Additional file 10: Table S13). As a
general finding, female patients seemed to have better
outcomes than male patients: all-cause 30-day mortality
was less likely for female patients (OR 0.60, p = 0.012,
95% CI [0.40, 0.89]), female patients were less likely to
be affected by invasive infection of sterile sites (OR 0.54,
p = 0.002, 95 % CI [0.37, 0.79]) and to be admitted to an
ICU (OR 0.63, p = 0.009, 95 % CI [0.45, 0.89]) (Table 2,
Additional file 10: Tables S13 - S14). Furthermore, in-
creasing CCI and increasing age seemed to be associated
with higher 30-day mortality (OR 1.16, p = 0.40, 95% CI
[1.01,1.34], and OR 1.36, p < 0.001, 95% CI [1.24,1.49],
respectively), whereas antibiotic treatment at entry or
during hospitalization was associated with higher odds
for ICU admission (OR 4.41, p < 0.001 and 95% CI
[2.10,8.93]) (Tables S15 – S16).
Strikingly, isolates of the K. oxytoca group were more
likely to be involved in invasive infection compared to
isolates of the K. pneumoniae group (OR 2.39, p = 0.044,
95% CI [1.05,5.53]). As we corrected in our model for
resistance against 3rd-generation cephalosporins, and as
the K. oxytoca group is not associated with a higher bur-
den of AMR, we hypothesize that this increased associ-
ation to invasive infections is independent of AMR and
might reflect increased virulence of this group.
We found no evidence for Klebsiella group- or
species-specific associations with the remaining clinical
outcomes (Additional file 10: Tables S14 – S17).
Discussion
We have described a MALDI-TOF MS method allowing
the identification of clinically important and currently
often misdiagnosed Klebsiella spp. and applied it to an
Table 2 Odds ratio estimates for invasive infection using the generalized linear mixed-effects model (GLMM). n = 732 complete
observations with 162 events. OR = odds ratio; CI = confidence interval; CCI = Charlson Comorbidity Index
OR 95 % CI Z p value
K. oxytocagroupvs. K. pneumoniaegroup 2.39 [1.05,5.53] 2.01 0.044
K. oxytocavs.K. michiganensis 0.75 [0.42,1.34] − 0.97 0.33
K. oxytoca vs. K. grimontii 0.64 [0.30,1.36] − 1.15 0.252
K. pneumoniae vs. K. variicola 1.08 [0.69,1.65] 0.35 0.724
K. pneumoniae vs. K. quasipneumoniae 0.64 [0.35,1.15] − 1.44 0.149
CCI 1.14 [1.04,1.25] 2.95 0.003
Age (centred, 10 years increase) 0.84 [0.75,0.95] − 2.78 0.005
Female (ratio) 0.54 [0.37,0.79] − 3.17 0.002
Immunosuppression 0.5 [0.29,0.86] − 2.5 0.012
Resistance to 3rd-generation cephalosporins 1.31 [0.44,3.74] 0.5 0.618
Antibiotic treatment at entry or during hospitalization 3.11 [1.44,6.49] 2.92 0.003
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international dataset of over 22,000 unique bacterial iso-
lates from microbiological routine laboratories. While
species-specific MALDI-TOF MS patterns within the
genus Klebsiella have previously been described [8, 25,
60], their discriminatory power has not yet been assessed
in large routinely acquired mass spectral datasets.
Using our ribosomal marker-based approach, we are
able to separate eight species of the genus Klebsiella: K.
pneumoniae, K. quasipneumoniae, K. variicola, “K. qua-
sivariicola”, K. oxytoca, K. michiganensis, K. grimontii
and K. huaxensis. This higher phylogenetic resolution
power represents an important step forward in clinical
diagnostics as “K. quasivariicola”, K. michiganensis, K.
grimontii and K. huaxensis are currently not found in
commonly used databases. Mass spectral quality plays
an important role in distinguishing the species within
the K. oxytoca group, as the species-specific peaks lie in
a high mass range with m/z values above 10,000. More-
over, in order to unambiguously identify the species K.
michiganensis, a unique combination of marker masses
in a higher mass range needs to be detected, posing an
additional challenge for identification. The inability to
detect these in many spectra decreases sensitivity. We
evaluated our approach by computing sensitivity and
specificity values for five clinically important Klebsiella
spp.. A limitation of the current study is that the most
recently described Klebsiella spp., K. africana, K. pas-
teurii and K. spallanzanii were not included in the ana-
lysis. Identifying species-specific marker masses for
these, and a similar evaluation for the less frequently ob-
served Klebsiella species would be desirable in future. A
recent study introduced a web-based tool which uses
other core proteins than ribosomal subunit proteins to
distinguish between the Klebsiella spp. [26]. Combining
these and our ribosomal marker masses could potentially
increase the resolution of MALDI-TOF mass spectral
identification, even below the species level.
Marker-based approaches are independent of the
MALDI-TOF MS system used. Therefore, we were able to
assess the occurrence and clinical phenotype of important
Klebsiella spp. in international clinical laboratories using
MALDI-TOF MS systems from different manufacturers.
While K. pneumoniae remains the most commonly de-
tected species, we also detected isolates from each of the
species, which are currently not routinely identified by
common MALDI-TOF MS databases, including K. qua-
sipneumoniae, “K. quasivariicola”, K. michiganensis, K. gri-
montii and K. huaxensis from a variety of patient material.
Our data provide evidence that infections with isolates of
the K. oxytoca group were more likely to be invasive than
infections with isolates of the K. pneumonia group,
highlighting the clinical importance of this under-
appreciated group. The clinical cases analysed in this study
were treated at the same healthcare centre in a low
endemic region for ESBL-producing bacteria. Further stud-
ies from different regions would be needed in order to con-
firm these results in other epidemiological backgrounds.
Due to the higher prevalence of the K. pneumoniae
group infections, a larger absolute number of invasive
infections are caused by isolates of the K. pneumoniae
group than by isolates of the K. oxytoca group. Thus, in-
fections with a K. oxytoca group isolate tend to be less
frequent, but more severe, a finding which could poten-
tially be linked to the increased frequency of certain
virulence factors, such as the siderophore yersiniabactin,
genes involved in allantoin metabolism and the cyto-
toxin tilivallin. Yersiniabactin and genes involved in the
allantoin metabolism are well established virulence fac-
tors of K. pneumoniae [61, 62], and their frequent occur-
rence in assemblies of the K. oxytoca group has been
observed before [21, 63]. Based on the data acquired in
this study, we describe an indirect link between the asso-
ciation of K. oxytoca group strains and invasive infection
and the occurrence of these virulence factors in genomes
of the same species. However, in order to assess whether
these factors actually increase the virulence of K. oxytoca
group strains, functional studies are needed.
Bloodstream infections caused by K. variicola have
been described as causing a higher mortality than blood-
stream infections caused by K. pneumoniae [64], a find-
ing that we could not confirm in our dataset.
Resistance to 3rd-generation cephalosporins is most
often conferred by ESBLs, which were enriched in the
analysed genomes of K. pneumoniae group compared to
the K. oxytoca group (Additional file 1: Figure S3).
Within the K. pneumoniae group isolates for which
spectra were analysed, we observed a higher proportion
of isolates resistant to 3rd- and 4th-generation cephalo-
sporins and aminoglycosides in K. pneumoniae com-
pared to K. variicola. The lower proportion of resistant
isolates within K. variicola has previously been described
[65] and is also in line with the lower frequency of ESBL
genes detected in K. variicola genome sequences, com-
pared to K. pneumoniae genome sequences. As genes
encoding AMR are often carried on plasmids, this may
be linked to the lower median number of plasmids de-
tected in isolates of K. variicola.
These findings need to be explored in other epidemio-
logical situations with higher ESBL and carbapenemase
burdens to examine their broader relevance. With this, a
rapid and accurate species identification by MALDI-
TOF MS may have an important impact on antibiotic
stewardship and treatment decisions.
Conclusions
Based on systematic comparison of WGS and in silico
ribosomal subunit protein mass prediction, we present a
MALDI-TOF MS-based analytical approach to
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distinguish eight Klebsiella species which can be applied
in clinical routine diagnostic laboratories. In this study,
we identified species-specific AMR and virulence pat-
terns within the genus Klebsiella and uncovered an in-
creased association of the K. oxytoca group with invasive
infection to primary sterile sites.
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